ReCare: first site active
We are very happy to announce that the first site for ReCare has been activated.
ReCare (EORTC 2011-RP) is a cohort of the E2-RADIatE platform that focuses on cancer patients who are treated with high-dose re-irradiation.
ReCare’s primary objective is to evaluate re-irradiated tumour control as well as safety of re-irradiation with regards to early and late toxicity for the different anatomic groups.
The ReCare cohort includes five subgroups, according to the anatomic areas of re-irradiation: the central nervous system (CNS), head and neck, thorax (including breast and chest wall), abdomen and pelvis. These subgroups will be open to patient accrual in 2 different phases.
Phase I is expected to include 500 patients undergoing re-irradiation treatment in the thorax, pelvis, and abdomen region. A total sample size of 2 000 patients is foreseen. 21 sites in 11 different countries were selected to participate in the first phase of this study.
The E²RADIatE platform is supported by Walgreens Boots Alliance.